scispace - formally typeset
L

Li Sun

Researcher at China Medical University (PRC)

Publications -  16
Citations -  299

Li Sun is an academic researcher from China Medical University (PRC). The author has contributed to research in topics: Kidney disease & Downregulation and upregulation. The author has an hindex of 9, co-authored 16 publications receiving 239 citations.

Papers
More filters
Journal ArticleDOI

High phosphorus level leads to aortic calcification via β-catenin in chronic kidney disease.

TL;DR: Investigation revealed that β-catenin transcriptionally regulated Pit1, a necessary player in VSMC osteogenic phenotype change and calcification, is an important player in high phosphorus level-induced aortic calcification in CKD.
Journal ArticleDOI

Role of Peritubular Capillary Loss and Hypoxia in Progressive Tubulointerstitial Fibrosis in a Rat Model of Aristolochic Acid Nephropathy

TL;DR: There was a progressive loss of PTCs in the AAN model, which was associated with the decreased expression of VEGF and a significant increase in nuclear localization of HIF-1α was seen 16 weeks after treatment with CAM decoction in the context of severe tubulointerstitial damage.
Journal ArticleDOI

Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats.

TL;DR: Pioglitazone attenuated renal injury and improved renal function and upregulated the expression levels of ATP synthase β, COX I and NDUFB8, which were downregulated in the kidney of Nx rats and TGF-β1-exposed HK-2 cells, which suggests that these effects at least partly PPARγ dependent.
Journal ArticleDOI

Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease: a meta-analysis.

TL;DR: O3FA supplementation is associated with lower several serum lipids and vascular inflammation markers in patients with ESRD, and has no significant effect on TC, HDL, albumin, hemoglobin, homocysteine, DBP, glucose, lipoprotein(a), and ferritin.
Journal ArticleDOI

Pioglitazone, a Peroxisome Proliferator-Activated Receptor x03B3; Agonist, Ameliorates Chronic Kidney Disease by Enhancing Antioxidative Capacity and Attenuating Angiogenesis in the Kidney of a 5/6 Nephrectomized Rat Model.

TL;DR: This study demonstrates that pioglitazone benefits renal failure through activation of the antioxidative system and inhibition of angiogenesis in the injured kidney.